Testing RLS-0071 for steroid-resistant acute graft-versus-host disease
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new drug, RLS-0071, for people who are hospitalized with acute graft-versus-host disease that hasn't improved with steroids. It aims to see if the drug is safe and can help control the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older.
- You are hospitalized for acute graft-versus-host disease (aGvHD) that did not respond to steroids.
- You have had only one stem cell transplant.
- You have not tried ruxolitinib for GvHD and had it fail.
- You are not on any other GvHD treatments besides steroids or ruxolitinib.
- You do not have active infections like sepsis, hepatitis B/C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called ruxolitinib for treating acute graft-versus-host disease (aGVHD), a common complication after a stem cell transplant. It may help control the immune reaction without using high doses of steroids.
This trial tests whether the drug ruxolitinib, given based on a blood test that predicts risk, can prevent chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It may help people who have a higher risk of developing this complication.
This trial tests adding ruxolitinib to standard drugs (tacrolimus and methotrexate) to prevent graft-versus-host disease in children and young adults undergoing a stem cell transplant for acute leukemia or myelodysplastic syndrome. The goal is to lower the risk of GVHD and improve transplant outcomes.
This trial tests new medications for people who develop severe acute graft-versus-host disease (aGVHD) within 100 days after their first stem cell transplant. The goal is to find safer, more effective ways to control aGVHD and improve recovery.
This trial tests whether adding ruxolitinib to standard steroid treatment works better than steroids alone for people with moderate to severe chronic graft-versus-host disease (cGVHD). cGVHD is a condition where donor immune cells attack the body after a stem cell transplant.
This trial tests whether adding stem cells (remestemcel-L) to ruxolitinib—a medication that helps control the immune system—can help treat severe graft-versus-host disease (GVHD) that hasn't responded to steroids. GVHD is a complication after bone marrow or stem cell transplant where the new immune cells attack your body.
Hear when a new Steroid Refractory GVHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.